Table 2 Adjusted association with time to CNS failure or death from Landmarks post 1st stereotactic radiosurgery

From: Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)

Patient Characteristics

Hazard Ratio

95% CI

P-value

Landmark 1

Systemic PD prior to LM1 vs not.

3.16

1.46, 6.83

0.0034

Age (per decade)

0.80

0.63, 1.01

0.0584

Race (white vs not white)

1.00

0.43, 2.32

0.9898

KPS 90–100 vs <90

0.49

0.27, 0.88

0.0186

ER + /Her2- vs Her2+

1.80

0.91, 3.53

0.0904

ER-/Her2- vs Her2+

2.77

1.23, 6.25

0.0142

Brain Mets at SRS1 ( > 1 vs 1)

2.40

1.30, 4.45

0.0052

PTV (per log)

0.98

0.80, 1.19

0.8173

Fractions (1 vs 3 or 5)

0.82

0.45, 1.50

0.5285

Landmark 2

Systemic PD prior to LM2 vs not.

5.32

2.33, 12.15

<0.0001

Age (per decade)

0.84

0.65, 1.10

0.2070

Race (white vs not white)

0.81

0.30, 2.20

0.6786

KPS 90–100 vs <90

0.85

0.43, 1.67

0.6290

ER + /Her2- vs Her2+

0.82

0.37, 1.81

0.6236

ER-/Her2- vs Her2+

1.26

0.48, 3.28

0.6336

Brain Mets at SRS1 ( > 1 vs 1)

2.18

1.05, 4.52

0.0367

PTV (per log)

1.05

0.83, 1.33

0.6932

Fractions (1 vs 3 or 5)

0.72

0.35, 1.45

0.3514